Eli Lilly and Company $LLY Shares Sold by Boston Common Asset Management LLC

Key Points

• Boston Common Asset Management trimmed its Eli Lilly stake by 16.3%, selling 5,754 shares and leaving 29,538 shares valued at about $31.74 million (LLY is ~1.6% of its portfolio and the firm's 12th-largest position).
• Corporate catalysts: the FDA approved Lilly’s oral GLP‑1 weight‑loss pill Foundayo and Lilly agreed to acquire Centessa Pharmaceuticals (up to ~$7.8B including milestones), moves that diversify revenue and helped spark a stock rally.
• Strong results and guidance: Lilly beat Q4 expectations with $7.54 EPS (vs. $7.48 est.) and $19.29B revenue (vs. $17.85B), set FY2026 EPS guidance of $33.50–35.00, and trades with a market cap near $903B as shares rose ~3.9%.

Boston Common Asset Management LLC trimmed its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 16.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 29,538 shares of the company's stock after selling 5,754 shares during the period. Eli Lilly and Company makes up about 1.6% of Boston Common Asset Management LLC's portfolio, making the stock its 12th biggest position. Boston Common Asset Management LLC's holdings in Eli Lilly and Company were worth $31,744,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in LLY. Vanguard Group Inc. lifted its position in Eli Lilly and Company by 0.7% during the third quarter. Vanguard Group Inc. now owns 80,959,089 shares of the company's stock valued at $61,771,785,000 after purchasing an additional 551,659 shares during the period. State Street Corp boosted its holdings in Eli Lilly and Company by 0.6% in the third quarter. State Street Corp now owns 34,726,558 shares of the company's stock valued at $26,496,364,000 after purchasing an additional 219,590 shares during the last quarter. Capital Research Global Investors grew its position in Eli Lilly and Company by 20.9% during the 3rd quarter. Capital Research Global Investors now owns 25,088,371 shares of the company's stock worth $19,141,787,000 after purchasing an additional 4,332,008 shares during the period. Wellington Management Group LLP grew its position in Eli Lilly and Company by 4.1% during the 3rd quarter. Wellington Management Group LLP now owns 14,563,780 shares of the company's stock worth $11,112,164,000 after purchasing an additional 574,229 shares during the period. Finally, Capital International Investors raised its stake in shares of Eli Lilly and Company by 6.1% during the 3rd quarter. Capital International Investors now owns 10,001,509 shares of the company's stock valued at $7,628,447,000 after buying an additional 579,381 shares during the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Trading Up 3.9%

Shares of LLY opened at $955.45 on Thursday. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,133.95. The stock has a market cap of $902.73 billion, a PE ratio of 41.63, a price-to-earnings-growth ratio of 1.07 and a beta of 0.51. The firm's fifty day moving average is $999.28 and its two-hundred day moving average is $966.87. The company has a quick ratio of 1.19, a current ratio of 1.58 and a debt-to-equity ratio of 1.54.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, beating analysts' consensus estimates of $7.48 by $0.06. The business had revenue of $19.29 billion during the quarter, compared to analysts' expectations of $17.85 billion. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The company's quarterly revenue was up 42.6% compared to the same quarter last year. During the same period in the prior year, the business earned $5.32 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: FDA approved Lilly’s oral GLP‑1 weight‑loss pill Foundayo — the approval opens a large, fast‑growing obesity market for a convenient daily pill (Lilly will sell Foundayo via LillyDirect with low listed cash prices and broad availability), which drove the stock rally. Lilly's weight-loss pill wins US approval, sets up next battle with rival Novo Nordisk - reuters.com
• Positive Sentiment: Lilly agreed to acquire Centessa Pharmaceuticals (up to ~$7.8B including milestones) to add orexin/OX2R sleep‑wake assets — diversification into neuroscience reduces concentration risk on GLP‑1s and supports longer‑term growth expectations. Eli Lilly to buy Centessa Pharma in $6.3 billion deal - Reuters
• Positive Sentiment: Unusual bullish options flow — large volume of call buying suggests traders positioned for further upside after the approval/announcements, amplifying intraday momentum. Eli Lilly Pops on GLP‑1 Pill Approval. Should You Buy LLY Stock Here? - Barchart
• Neutral Sentiment: Competitive dynamics — Novo Nordisk is responding with subscription pricing for Wegovy and other tactics; Foundayo’s pricing/coverage and real‑world adoption vs. Wegovy will determine market share, so near‑term upside could be capped by competition. Novo Nordisk (NVO) Stock: New Wegovy Subscription Pricing Takes on Eli Lilly - Blockonomi
• Negative Sentiment: Policy and pricing risk — Lilly’s CEO publicly opposed codifying 'Most Favored Nations' drug‑pricing deals into law, highlighting ongoing regulatory/political risks that could pressure pricing or margins over time. Eli Lilly opposes push to pass Trump's drug pricing deals into law, CEO says - CNBC

Analyst Ratings Changes

Several equities analysts have recently issued reports on LLY shares. Deutsche Bank Aktiengesellschaft reissued a "buy" rating and issued a $1,285.00 price objective on shares of Eli Lilly and Company in a report on Friday, March 6th. UBS Group reissued a "buy" rating on shares of Eli Lilly and Company in a report on Wednesday, March 18th. The Goldman Sachs Group set a $1,260.00 price objective on Eli Lilly and Company in a research report on Thursday, February 5th. Wall Street Zen raised shares of Eli Lilly and Company from a "buy" rating to a "strong-buy" rating in a research note on Sunday. Finally, Berenberg Bank lifted their target price on shares of Eli Lilly and Company from $950.00 to $1,050.00 and gave the company a "hold" rating in a report on Thursday, February 19th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $1,221.26.

Eli Lilly and Company Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.